Attached files
Exhibit 32.1
CERTIFICATION PURSUANT
TO
18 U.S.C. SECTION
1350,
AS ADOPTED PURSUANT
TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of AzurRx
BioPharma, Inc. (the “Company”) on Form 10-Q for the period ended March
31, 2021 as filed with the Securities and Exchange Commission on
the date hereof (the “Report”), I, James Sapirstein, Chief Executive
Officer of the Company, and Daniel
Schneiderman, Chief Financial Officer of the Company, each
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002,
that:
|
(1)
The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and
|
|
(2)
The information contained in the Report fairly presents, in all
material respects, the financial condition and results of
operations of the Company.
|
Date: May 24, 2021
|
/s/
James Sapirstein
|
|
James Sapirstein
President
and Chief Executive Officer
(Principal
Executive Officer)
|
|
|
|
|
|
/s/
Daniel
Schneiderman
Daniel
Schneiderman
Chief
Financial Officer
(Principal
Financial and Accounting Officer)
|
|
|